Zollinger‑Ellison Disease (MEN‑1 Associated)
Overview
Zollinger‑Ellison disease (ZED) is a rare neuroendocrine tumor that originates in the pancreas or duodenum and secretes very high levels of gastrin, a hormone that stimulates the stomach to produce acid. When ZED occurs as part of multiple endocrine neoplasia type 1 (MEN‑1), patients often develop other endocrine tumors (parathyroid, pituitary) in addition to the gastrin‑producing tumor.
Key points:
- Prevalence: Sporadic ZED occurs in ~1‑3 per million people worldwide. MEN‑1 associated ZED accounts for about 20‑30 % of all Zollinger‑Ellison cases.[1]
- Age: Median age at diagnosis is 40–50 years; MEN‑1 patients may develop ZED a decade earlier.
- Gender: Slight male predominance in sporadic disease; MEN‑1 shows no clear gender bias.
- Inheritance: MEN‑1 is autosomal‑dominant, caused by mutations in the MEN1 tumor‑suppressor gene.
Symptoms
Because excess gastric acid damages the gastrointestinal lining, symptoms stem from peptic ulcer disease, malabsorption, and the hormonal effects of the tumor.
Gastro‑intestinal symptoms
- Refractory peptic ulcers: Ulcers that recur despite treatment, often located in the duodenum, jejunum, or even the distal small intestine.
- Abdominal pain: Burning or gnawing pain that may improve or worsen after eating.
- Diarrhea: Occurs in up to 50 % of patients due to acid‑induced injury to the intestinal mucosa and rapid transit.
- Steatorrhea (fatty stools): Malabsorption of fats caused by acid inactivation of pancreatic enzymes.
- Nausea & vomiting: Especially after large meals.
- Gastro‑intestinal bleeding: Hematemesis or melena from ulcer erosion.
Systemic symptoms
- Weight loss: Due to malabsorption and chronic diarrhea.
- Fatigue & anemia: Chronic blood loss and vitamin B12 deficiency.
- Osteopenia/osteoporosis: More common in MEN‑1 patients who also have hyperparathyroidism.
MEN‑1 specific manifestations (may coexist)
- Hyperparathyroidism: Calcium excess leading to kidney stones, bone pain, psychiatric changes.
- Pituitary adenomas: Headaches, visual field defects, hormonal excess (e.g., prolactin, growth hormone).
Causes and Risk Factors
Genetic basis
MEN‑1 associated ZED results from germline mutations in the MEN1 gene (chromosome 11q13). The mutated menin protein fails to regulate cell growth, predisposing pancreatic/duodenal neuroendocrine cells to become gastrin‑producing tumors.
Risk factors
- Family history of MEN‑1: First‑degree relatives have a 50 % chance of inheriting the mutation.
- Known MEN1 mutation: Even asymptomatic carriers are at risk.
- Age: Tumor development increases after the third decade of life.
- Smoking: May accelerate tumor growth, though evidence is limited.
Non‑genetic (sporadic) ZED
Most ZED cases are sporadic, arising from somatic mutations in the MEN1 gene or VHL and ATRX genes. Lifestyle factors have not been proven to cause ZED.
Diagnosis
Diagnosis combines clinical suspicion, biochemical testing, imaging, and sometimes histology.
Biochemical tests
- Fasting serum gastrin: Levels > 1,000 pg/mL are highly suggestive. Values between 100–1,000 pg/mL require provocative testing.
- Secretin stimulation test: Administration of secretin normally suppresses gastrin; in ZED, gastrin paradoxically rises ≥ 120 pg/mL.
- Basal acid output (BAO) or gastric pH: Very low pH (< 2) confirms hyperacidity.
- Calcium & PTH: Screen for hyperparathyroidism in MEN‑1 patients.
Imaging studies
- Multiphasic contrast CT or MRI of the abdomen: Detects primary gastrinoma and liver metastases.
- Endoscopic ultrasound (EUS): Highly sensitive for <1 cm pancreatic lesions.
- Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT: Identifies occult or metastatic disease because gastrinomas overexpress somatostatin receptors.
- Selective arterial secretagogue injection (SASI) test: Rare, used when imaging is inconclusive.
Pathology (if surgery performed)
Tumor tissue shows neuroendocrine features (chromogranin A, synaptophysin positive) and secretes gastrin on immunohistochemistry.
Diagnostic criteria summary
- Clinical syndrome of refractory ulcer disease + secretory diarrhea.
- Fasting gastrin > 1,000 pg/mL **or** positive secretin test.
- Imaging localizes a gastrin‑secreting tumor.
- Exclusion of other causes of hypergastrinemia (e.g., chronic PPI use, atrophic gastritis).
Treatment Options
Management aims to control acid hypersecretion, eradicate or control the tumor, and address MEN‑1 related lesions.
1. Acid‑suppression therapy (first line)
- High‑dose proton‑pump inhibitors (PPIs): Omeprazole 40–80 mg daily, pantoprazole 80–120 mg daily, or equivalent. PPIs normalize gastric pH in > 90 % of patients.[2]
- H2‑receptor antagonists: May be added for breakthrough symptoms, but PPIs remain the cornerstone.
- Monitor serum magnesium, calcium, and vitamin B12** levels** annually because chronic PPI use can cause deficiencies.
2. Surgical management
- Curative resection: Preferred for localized gastrinomas (≤ 2 cm) without metastasis. Procedures include:
- Pancreaticoduodenectomy (Whipple) for duodenal/ampullary lesions.
- Enucleation for small, well‑circumscribed tumors.
- Debulking surgery: For metastatic disease, reduces tumor burden and improves symptom control.
- Management of MEN‑1 lesions: Simultaneous parathyroidectomy or pituitary surgery may be indicated.
3. Medical therapies for tumor control
- Somatostatin analogues (SSA): Octreotide or lanreotide bind somatostatin receptors, lowering gastrin secretion and may stabilize tumor growth.[3]
- Targeted therapy (everolimus): An mTOR inhibitor approved for advanced pancreatic neuroendocrine tumors; modest effect on gastrin levels.
- Peptide receptor radionuclide therapy (PRRT): ^177Lu‑DOTATATE can shrink somatostatin‑receptor positive metastases.
- Chemotherapy: Rarely needed; streptozocin‑based regimens are used for aggressive disease.
4. Lifestyle & supportive measures
- Avoid NSAIDs, aspirin, and smoking – they aggravate ulcer formation.
- Small, frequent meals; limit high‑fat foods that stimulate acid release.
- Calcium and vitamin D supplementation if hyperparathyroidism is present or after parathyroid surgery.
Living with Zollinger‑Ellison Disease (MEN‑1 associated)
Medication adherence
- Take PPIs exactly as prescribed; never skip doses.
- Set reminders for intermittent SSA injections or oral doses.
- Carry a list of current medications, especially if you are on multiple endocrine therapies.
Monitoring schedule
| Test | Frequency |
|---|---|
| Fasting gastrin & gastric pH | Every 6–12 months (or sooner if symptoms change) |
| Calcium, PTH, vitamin D | Annually or after parathyroid surgery |
| Cross‑sectional imaging (CT/MRI) | Every 12–24 months for localized disease; every 6 months if metastatic |
| Bone density (DEXA) | Every 2–3 years |
| Endoscopy | Every 1–2 years to assess ulcer healing |
Nutrition tips
- Favor low‑acid foods (e.g., oatmeal, bananas) during flare‑ups.
- Include protein‑rich, easily digested foods to prevent malnutrition.
- Stay hydrated; oral rehydration solutions help replace electrolytes lost in chronic diarrhea.
Psychosocial support
Living with a chronic endocrine condition can be stressful. Consider:
- Joining support groups (e.g., MEN‑1 Association, ZES patient forums).
- Regular counseling or therapy to address anxiety about cancer recurrence.
- Genetic counseling for family planning.
Prevention
Because MEN‑1 is inherited, true primary prevention is not possible, but measures can reduce disease burden:
- Genetic screening: Immediate testing of first‑degree relatives of an affected individual allows early surveillance.
- Annual biochemical surveillance: Early detection of hypergastrinemia or hyperparathyroidism can prompt treatment before complications develop.
- Healthy lifestyle: Avoid tobacco and limit alcohol, as both can exacerbate ulcer disease.
- Prompt treatment of Helicobacter pylori: Eradication eliminates an additional ulcer‑promoting factor.
Complications
If left untreated or inadequately controlled, ZED can lead to serious outcomes:
- Perforated ulcer: Abdominal emergency with peritonitis.
- Severe gastrointestinal bleeding: May require transfusion or endoscopic intervention.
- Sepsis from ulcer perforation or infected necrotic tissue.
- Malnutrition and weight loss: Resulting from chronic diarrhea and steatorrhea.
- Bone disease: Osteopenia/osteoporosis from chronic acid loss of calcium and MEN‑1 related hyperparathyroidism.
- Metastatic gastrinoma: Liver, lymph node, or peritoneal spread in 30‑50 % of patients; associated with poorer prognosis.
- Secondary cancers: MEN‑1 patients have increased risk of pancreatic neuroendocrine carcinoma and thymic or bronchial carcinoids.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department if you experience any of the following:
- Sudden, severe abdominal pain that does not improve with medication.
- Vomiting blood (bright red or “coffee‑ground” material).
- Black, tarry stools (melena) indicating gastrointestinal bleeding.
- High fever (> 101 °F / 38.3 °C) with abdominal pain – possible perforation or infection.
- Rapid heart rate, dizziness, or fainting – signs of significant blood loss or dehydration.
- Severe, persistent diarrhea leading to weakness, confusion, or inability to keep fluids down.
Prompt treatment can be life‑saving.
Sources:
- Wang J, et al. “Management of Zollinger‑Ellison Syndrome in the Era of MEN1.” Frontiers in Endocrinology. 2020;11:578.
- Cleveland Clinic. “Zollinger‑Ellison Syndrome.” Updated 2022. https://my.clevelandclinic.org/health/diseases/14785-zollinger-ellison-syndrome
- Strosberg J, et al. “Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors.” NEJM. 2017;376:125–135.
- Mayo Clinic. “Multiple Endocrine Neoplasia Type 1 (MEN1).” Accessed 2023. https://www.mayoclinic.org/diseases-conditions/multiple-endocrine-neoplasia-type-1
- National Cancer Institute. “Neuroendocrine Tumors Treatment (PDQ®)–Health Professional Version.” 2022. https://www.cancer.gov/types/neuroendocrine